SAGE Therapeutics, Inc.
(NASDAQ : SAGE)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
VRXValeant Pharmaceuticals International, Inc. -2.71%28.4014.1%$167.11m
AMRNAmarin Corp. Plc -2.60%20.221.7%$161.85m
AXSMAxsome Therapeutics, Inc. -2.92%85.201.9%$90.60m
BHCBausch Health Cos., Inc. -2.71%28.400.0%$84.60m
GWPHGW Pharmaceuticals Plc -1.20%114.516.2%$73.62m
JAZZJazz Pharmaceuticals Plc -2.25%145.742.3%$63.95m
PRGOPerrigo Co. Plc -1.24%58.746.8%$63.73m
ICPTIntercept Pharmaceuticals, Inc. -3.02%96.6516.9%$61.51m
SAVACassava Sciences, Inc. -7.18%7.180.0%$60.84m
SAGESAGE Therapeutics, Inc. -3.46%68.028.6%$58.61m
HZNPHorizon Therapeutics Plc -2.83%36.066.6%$56.41m
MNKMallinckrodt Plc -7.68%5.1720.9%$43.68m
ICLRICON plc 0.09%174.954.2%$39.55m
CTLTCatalent, Inc. 0.05%61.602.4%$37.97m
UTHRUnited Therapeutics Corp. -1.70%89.3314.3%$34.80m

Company Profile

SAGE Therapeutics, Inc. operates as clinical stage biopharmaceutical company, which engages in the development and commercialization of novel medicines to treat life-altering central nervous system. Its programs include brexanolone, which is an acute interventional treatment for postpartum depression; and SAGE-217, an oral therapy for treatment of various CNS disorders. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.